The role of focal therapy in prostate cancer for kidney transplant patients
This e-course will present evidence which will demonstrate the role of focal therapy as an alternative in the management of a heterogeneous disease such as prostate cancer (PCa) in the high-risk population of kidney transplant patients and/or candidates.
|Organiser||ESU (European School of Urology)|
|Duration||Approx. 60 minutes|
Organ-sparing approaches in the management of localised PCa were developed in part to overcome the morbidity associated with standard whole-gland treatment options. This can be crucial in kidney transplant patients and/or candidates.
Focal therapy was introduced and defined over two decades ago and since then, substantial developments have taken place. The evolution of patient selection; the approach to ablation; surveillance after focal therapy; and improved understanding of the biology of low-grade, low-risk PCa have mirrored the technological advancements in the field.
Prof. Dr. E. Lledó García (ES)
Dr. E. Barret (FR)
Dr. C. Martinez Ballesteros (ES)
Prof. Dr. J.I. Martínez Salamanca (ES)
Contact our organiser
ESU (European School of Urology)